ମାଇକୋଫେନୋଲିକ ଏସିଡ

ମାଇକୋଫେନୋଲିକ ଏସିଡ
Clinical data
Pronunciation	/ˌmaɪkoʊfɪˈnɒlɪk/
Trade names	CellCept, Myfortic, others
Synonyms	Mycophenolate sodium, mycophenolate mofetil
AHFS/Drugs.com	monograph
MedlinePlus	a601081
data	US DailyMed: Mycophenolate_mofetil;
Pregnancy; category	AU: D ; US: D (Evidence of risk) ;
Routes of; administration	By mouth, intravenous
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; UK: POM (Prescription only) ; US: ℞-only ; ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	72% (sodium),; 94% (mofetil)
Protein binding	82–97%
Metabolism	Liver
Elimination half-life	17.9±6.5 hours
Excretion	Urine (93%),; faeces (6%)
Identifiers
	IUPAC name (4E)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid;
ECHA InfoCard	100.041.912
Chemical and physical data
Formula	C17H20O6
Molar mass	୩୨୦.୩୪ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1OCc2c1c(O)c(c(OC)c2C)C\C=C(/C)CCC(=O)O;
	InChI InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+ ; Key:HPNSFSBZBAHARI-RUDMXATFSA-N ;
(verify)

ମାଇକୋଫେନୋଲିକ ଏସିଡ ( MPA ), ଅନ୍ୟ ନାମ ମାଇକୋଫେନୋଲେଟ, ଏକ ଇମ୍ମ୍ୟୁନୋସପ୍ରେସାଣ୍ଟ ଔଷଧ ଯାହା ଯାହା ଅଙ୍ଗ ପ୍ରତିରୋପଣ ପରବର୍ତ୍ତୀ ପ୍ରତ୍ୟାଖ୍ୟନ‌କୁ ରୋକିବା ପାଇଁ ଏବଂ କ୍ରନ ରୋଗ, ସିସ୍ଟମିକ ଲୁପସ୍ ଏରିଦେମାଟୋସସ୍, ଇଣ୍ଟରଷ୍ଟିସିଆଲ ଫୁସଫୁସ ରୋଗ ଏବଂ ସ୍କ୍ଲେରୋଡର୍ମା ରୋଗମାନଙ୍କର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ | ^[୪] ^[୫] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ବୃକ୍‌କ, ହୃତ୍‌ପିଣ୍ଡ ଏବଂ ଯକୃତ ପ୍ରତିରୋପଣ ପରେ ବ୍ୟବହୃତ ହୁଏ | ^[୬] ଏହା ପାଟିରେ କିମ୍ବା ଶିରାରେ ଇଞ୍ଜେକ୍ସନ‌ଦ୍ୱାରା ଦିଆଯାଇପାରେ | ^[୬] ଏହା ମାଇକୋଫେନୋଲେଟ ସୋଡିୟମ୍ ଏବଂ ମାଇକୋଫେନୋଲେଟ୍ ମୋଫେଟିଲ୍ ( MMF ) ଭାବରେ ଆସେ | ^[୬]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ବାନ୍ତି, ସଂକ୍ରମଣ ଏବଂ ତରଳ ଝଡ଼ା ହୁଏ | ^[୫] ଅନ୍ୟାନ୍ୟ ଗମ୍ଭୀର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ କର୍କଟ, ପ୍ରଗତିଶୀଳ ମଲ୍ଟିଫୋକାଲ ଲ୍ୟୁକୋଏନସେଫାଲୋପାଥି, ରକ୍ତହୀନତା ଏବଂ ଖାଦ୍ୟନଳୀ ରକ୍ତସ୍ରାବ ହେବାର ଆଶଙ୍କା ରହିଛି। ^[୬] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି କରିପାରେ | ^[୬] ଏହି ଔଷଧ ପିତା ନେଲେ ତାହାର ପ୍ରଭାବ ଅସ୍ପଷ୍ଟ ଅଛି | ^[୭] ମାଇକୋଫେନୋଲିକ ଏସିଡ ରୋଗ ପରିବର୍ତ୍ତନ‌କାରୀ ଆଣ୍ଟିରିଉମାଟିକ (DMARDs) ପରିବାରର ଏକ ଔଷଧ ଅଟେ | ^[୪] ଏହା ଇନୋସିନ ମୋନୋଫସଫେଟ ଡିହାଇଡ୍ରଜେନେଜକୁ (IMPDH) ଅବରୋଧ କରି କାର୍ଯ୍ୟ କରିଥାଏ, ଯାହା ଗୁଆନୋସିନ ତିଆରି କରିବା ପାଇଁ ଲୋମ୍ଫସାଇଟ ଆବଶ୍ୟକ କରେ | ^[୬]

ମାଇକୋଫେନୋଲିକ୍ ଏସିଡ୍ ପ୍ରଥମେ ୧୮୯୩ ମସିହାରେ ଇଟାଲୀର ବାର୍ଟୋଲୋମିଓ ଗୋସିଓଙ୍କଦ୍ୱାରା ଆବିଷ୍କୃତ ହୋଇଥିଲା | ^[୮] ^[୯] ଏହା ୧୯୪୫ ଏବଂ ୧୯୬୮ ମସିହାରେ ପୁନଃ ଆବିଷ୍କୃତ ହୋଇଥିଲା । ^[୧୦] ୧୯୯୦ ଦଶକରେ ଏହାର ଇମ୍ୟୁନୋସପ୍ରେସିଭ୍ ଗୁଣ ଆବିଷ୍କାର ପରେ ୧୯୯୫ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଏହା ଅନୁମୋଦିତ ହୋଇଥିଲା। ^[୫] ^[୧୧] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ | ^[୭] ଯୁକ୍ତରାଜ୍ୟରେ ୧.୫ ଗ୍ରାମର ଦୁଇ ଡୋଜ ନେବାକୁ ଏହି ଔଷଧ ପିଛା୨୦୨୧ ମସିହାରେ ଏନଏଚଏସକୁ ମାସରେ ପ୍ରାୟ ୨୫ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ କରିବାକୁ ପଡ଼େ । ^[୧୨] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ମୂଲ୍ୟ ପ୍ରାୟ ୧୧୪ ଆମେରିକୀୟ ଡଲାର | ^[୧୩] ୨୦୧୭ ମସିହାରେ ଏହା ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୫୪ତମ ସାଧାରଣ ପ୍ରେସକ୍ରିପସନ ଔଷଧ ଥିଲା, ଯେଉଁଥିରେ ଏକ ନିୟୁତରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ୍ ରହିଥିଲା | ^[୧୪] ^[୧୫]

ଆଧାର

1 2 "Mycophenolate mofetil (CellCept) Use During Pregnancy". Drugs.com. 24 January 2020. Retrieved 6 April 2020.
↑ Jasek W, ed. (2007). Austria-Codex (in German) (62nd ed.). Vienna: Österreichischer Apothekerverlag. pp. 1484–95. ISBN 978-3-85200-181-4.{{cite book}}: CS1 maint: unrecognized language (link)
1 2 3 4 5 "CellCept" (PDF). TGA eBusiness Services. Roche Products Pty Limited. 13 December 2012. Retrieved 25 February 2014.
1 2 Shagroni, T.; Cazares, Ramirez; Kim, J. A.; Furst, Daniel E. (2020). "36. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics, & drugs used in gout". In Katzung, Bertram G.; Trevor, Anthony J. (eds.). Basic and Clinical Pharmacology (in ଇଂରାଜୀ) (15th ed.). New York: McGraw-Hill. p. 678. ISBN 978-1-260-45231-0.
1 2 3 "Mycophenolate Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 28 October 2019.
1 2 3 4 5 6 "Mycophenolate Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 28 October 2019.
1 2 "8. Immune system and malignant disease". British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. pp. 895–897. ISBN 978-0-85711-413-6.{{cite book}}: CS1 maint: date format (link)
↑ Schiff, Eugene R.; Maddrey, Willis C.; Sorrell, Michael F. (2011). Schiff's Diseases of the Liver (in ଇଂରାଜୀ). John Wiley & Sons. p. PT3219. ISBN 978-1-119-95048-6.
↑ Laskin, Allen I.; Bennett, Joan W.; Gadd, Geoffrey M. (2001). Advances in Applied Microbiology (in ଇଂରାଜୀ). Gulf Professional Publishing. p. 236. ISBN 978-0-12-002648-7.
↑ Laskin, Allen I.; Bennett, Joan W.; Gadd, Geoffrey M. (2001). Advances in Applied Microbiology (in ଇଂରାଜୀ). Gulf Professional Publishing. p. 236. ISBN 978-0-12-002648-7.
↑ Schiff, Eugene R.; Maddrey, Willis C.; Sorrell, Michael F. (2011). Schiff's Diseases of the Liver (in ଇଂରାଜୀ). John Wiley & Sons. p. PT3219. ISBN 978-1-119-95048-6.
↑ "8. Immune system and malignant disease". British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. pp. 895–897. ISBN 978-0-85711-413-6.{{cite book}}: CS1 maint: date format (link)
↑ "Mycophenolate mofetil Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Retrieved 29 October 2019.
↑ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
↑ "Mycophenolate Mofetil - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

[Drugs.com_pregnancy-1] 1 2 "Mycophenolate mofetil (CellCept) Use During Pregnancy". Drugs.com. 24 January 2020. Retrieved 6 April 2020.

[Austria-Codex-2] Jasek W, ed. (2007). Austria-Codex (in German) (62nd ed.). Vienna: Österreichischer Apothekerverlag. pp. 1484–95. ISBN 978-3-85200-181-4.{{cite book}}: CS1 maint: unrecognized language (link)

[TGA-3] 1 2 3 4 5 "CellCept" (PDF). TGA eBusiness Services. Roche Products Pty Limited. 13 December 2012. Retrieved 25 February 2014.

[Katzung2021-4] 1 2 Shagroni, T.; Cazares, Ramirez; Kim, J. A.; Furst, Daniel E. (2020). "36. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics, & drugs used in gout". In Katzung, Bertram G.; Trevor, Anthony J. (eds.). Basic and Clinical Pharmacology (in ଇଂରାଜୀ) (15th ed.). New York: McGraw-Hill. p. 678. ISBN 978-1-260-45231-0.

[AHFS2019-5] 1 2 3 "Mycophenolate Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 28 October 2019.

[autogen4-6] 1 2 3 4 5 6 "Mycophenolate Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 28 October 2019.

[BNF82-7] 1 2 "8. Immune system and malignant disease". British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. pp. 895–897. ISBN 978-0-85711-413-6.{{cite book}}: CS1 maint: date format (link)

[Sch2011-8] Schiff, Eugene R.; Maddrey, Willis C.; Sorrell, Michael F. (2011). Schiff's Diseases of the Liver (in ଇଂରାଜୀ). John Wiley & Sons. p. PT3219. ISBN 978-1-119-95048-6.

[Las2011-9] Laskin, Allen I.; Bennett, Joan W.; Gadd, Geoffrey M. (2001). Advances in Applied Microbiology (in ଇଂରାଜୀ). Gulf Professional Publishing. p. 236. ISBN 978-0-12-002648-7.

[autogen2-10] Laskin, Allen I.; Bennett, Joan W.; Gadd, Geoffrey M. (2001). Advances in Applied Microbiology (in ଇଂରାଜୀ). Gulf Professional Publishing. p. 236. ISBN 978-0-12-002648-7.

[autogen1-11] Schiff, Eugene R.; Maddrey, Willis C.; Sorrell, Michael F. (2011). Schiff's Diseases of the Liver (in ଇଂରାଜୀ). John Wiley & Sons. p. PT3219. ISBN 978-1-119-95048-6.

[autogen7-12] "8. Immune system and malignant disease". British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. pp. 895–897. ISBN 978-0-85711-413-6.{{cite book}}: CS1 maint: date format (link)

[ref-13] "Mycophenolate mofetil Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Retrieved 29 October 2019.

[ref1-14] "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.

[ref2-15] "Mycophenolate Mofetil - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]

[୧୦]

[୧୧]

[୧୨]

[୧୩]

[୧୪]

[୧୫]